Other languages Adicet Bio, Inc.

Equities

ACET

US0070021086

Real-time Estimate Cboe BZX Other stock markets 01:52:26 2024-04-29 pm EDT			5-day change	1st Jan Change
1.66 ^USD	-1.19%		-17.00%	-12.17%

Apr. 22	Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting	CI
Mar. 26	North American Morning Briefing : Markets Steady -2-	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting	Apr. 22
Adicet Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19
Adicet Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19
Sector Update: Health Care Stocks Mixed Premarket Tuesday	Jan. 23
Adicet Bio Launches Securities Offering; Shares Rise After-Hours	Jan. 22
Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting	Dec. 10
Adicet Bio, Inc. Announces Board Changes	Nov. 13
Adicet Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Adicet Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors	23-07-11
Insider Buy: Adicet Bio	23-06-29
Adicet Bio Reports Positive Phase 1 Data for Treatment of Non-Hodgkin's Lymphoma; Shares Drop Premarket	23-06-27
Adicet Bio Reports Positive Data From ADI-001 Study for Treatment of Non-Hodgkin's Lymphoma; Shares Fall After Hours	23-06-26
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkinâ€™s Lymphoma	23-06-26
Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy 26Th Annual Meeting	23-05-18
Adicet Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09
Bivictrix promotes non-executive director to non-executive chair	23-01-06
Adicet Bio Shares Fall After Release of Cancer Phase 1 Trial Data	22-12-12
Wall Street Set to Open Higher as Investors Await Inflation Data, Fed Rate Decision in Coming Days	22-12-12
US Futures Move Modestly Higher Monday Ahead of Inflation Data Tuesday, Fed Rate Decision Meeting Conclusion Wednesday	22-12-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Adicet Bio, Inc.

Equities

ACET

US0070021086

Other languages

Filters